RESUMO
The determination of nimodipine in the presence of its degradation products, formed through photolysis, acidic and alkaline hydrolysis, and the drug degradation kinetics under these conditions, was investigated through a validated liquid chromatography method. Separation was achieved using a Phenomenex Luna C18 column (250 × 4.6 mm i.d., 5 µm) with a mobile phase consisting of acetonitrile-methanol-water (55:11:34, v/v/v), at 0.5 mL/min and with ultraviolet detection at 235 nm. The method was considered to be specific, accurate, precise, robust and linear over the concentration range of 5.0 to 35.0 µg/mL. The drug followed a first-order reaction for both hydrolysis and photolysis in methanol, and zero-order for photolysis in acetonitrile and water. The calculated activation energies were 10.899 and 23.442 kcal/mol for alkaline and acidic hydrolysis, respectively. No degradation was observed under thermal and oxidative stress conditions.
Assuntos
Cromatografia Líquida/métodos , Nimodipina/análise , Análise de Variância , Estabilidade de Medicamentos , Ácido Clorídrico , Hidrólise , Cinética , Modelos Lineares , Nimodipina/química , Fotólise , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Hidróxido de Sódio , TemperaturaRESUMO
The present study reports the solid-state properties of Fluvastatin sodium salt crystallized from different solvents for comparison with crystalline forms of the commercially available raw material and United States Pharmacopeia (USP) reference standard. Fluvastatin (FLV) samples were characterized by several techniques; such as X-ray powder diffractometry, differential scanning calorimetry, thermogravimetry, liquid and solid-state nuclear magnetic resonance spectroscopy, diffuse reflectance infrared Fourier transform spectroscopy, and scanning electron microscopy. In addition, intrinsic dissolution rate (IDR) of samples was performed in order to study the influence of crystalline form and other factors on rate and extent of dissolution. Three different forms were found. The commercial raw material and Fluvastatin-Acetonitrile (ACN) were identified as "form I" hydrate, the USP reference standard as "form II" hydrate and an ethanol solvate which presented a mixture of phases. Form I, with water content of 4%, was identified as monohydrate.
Assuntos
Ácidos Graxos Monoinsaturados/química , Indóis/química , Varredura Diferencial de Calorimetria/métodos , Cristalização/métodos , Fluvastatina , Espectroscopia de Ressonância Magnética/métodos , Microscopia Eletrônica de Varredura/métodos , Solubilidade , Solventes/química , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Termogravimetria/métodos , Difração de Raios X/métodosRESUMO
An HPLC method was developed and validated for the simultaneous determination of buclizine, tryptophan, pyridoxine, and cyanocobalamin in pharmaceutical formulations. The chromatographic separation was carried out on an RP-C18 column using a mobile phase gradient of methanol, 0.015 M phosphate buffer (pH 3.0), and 0.03 M phosphoric acid at a flow rate of 1.0 mL/min and UV detection at 230, 280, and 360 nm, respectively, for buclizine, tryptophan, pyridoxine, and cyanocobalamin. The method validation yielded good results with respect to linearity (r>0.999), specificity, precision, accuracy, and robustness. The RSD values for intraday and interday precision were below 1.82 and 0.63%, respectively, and recoveries ranged from 98.11 to 101.95%. The method was successfully applied for the QC analysis of buclizine, tryptophan, pyridoxine, and cyanocobalamin in tablets and oral suspension.
